PRESS RELEASE published on 11/13/2025 at 17:57, 7 months 10 days ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management pour le compte de CVI Investments, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils GENSIGHT BIOLOGICS SA Heights Capital Management CVI Investments Inc.
BRIEF published on 10/30/2025 at 07:35, 7 months 24 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 10/30/2025 at 07:35, 7 months 24 days ago GenSight Biologics : Feu vert pour un traitement compassionnel aux États-Unis FDA GenSight Biologics NOHL Accès Compassionnel GS010/LUMEVOQ®
PRESS RELEASE published on 10/30/2025 at 07:30, 7 months 24 days ago Informations privilégiées / Autres communiqués GenSight Biologics a obtenu les autorisations réglementaires pour un traitement compassionnel aux États-Unis avec GS010/LUMEVOQ, visant la Neuropathie Optique Héréditaire de Leber FDA GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ Traitement Compassionnel
BRIEF published on 09/29/2025 at 23:05, 8 months 23 days ago GenSight Biologics annonce ses résultats financiers du premier semestre 2025 Résultats Financiers Recherche Et Développement Trésorerie GenSight Biologics Programmes D'accès Précoce
BRIEF published on 09/29/2025 at 23:05, 8 months 23 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 8 months 23 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie résultats financiers du premier semestre 2025 : gestion optimisée de trésorerie, financement post-clôture, transfert de fabrication, protocole d'étude soumis à l'ANSM Résultats Financiers Financement Trésorerie GenSight Biologics Étude ANSM
PRESS RELEASE published on 09/29/2025 at 23:00, 8 months 23 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 8 months 23 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 9 months 25 days ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
Published on 06/23/2026 at 16:10, 2 hours 58 minutes ago Datavault AI Inc. (NASDAQ: DVLT) and WiSA Technologies Announce the Goho LS7 2.0 and 5.1 Home Theater Systems with WiSA E Wireless Connectivity
Published on 06/23/2026 at 16:00, 3 hours 8 minutes ago Secure Blockchain Appoints Former Polygon Executive Steven Bryson-Haynes as CEO to Drive Enterprise AI Commercialization
Published on 06/23/2026 at 15:45, 3 hours 23 minutes ago Amdocs Advances aOS Network Workflows with Live, Multivendor AI-RAN Solution and Industry Blueprint
Published on 06/23/2026 at 15:30, 3 hours 38 minutes ago Silver Spruce Resources, Inc. Adds Mine Production Knowledge to the Board
Published on 06/23/2026 at 15:30, 3 hours 38 minutes ago Galantas Gold Completes Transaction to Acquire Andacollo Gold
Published on 06/23/2026 at 18:30, 38 minutes ago IEVA GROUP: COMPTE RENDU DE L’ASSEMBLÉE GÉNÉRALE ORDINAIRE ANNUELLE DU 23 JUIN 2026
Published on 06/23/2026 at 17:55, 1 hour 12 minutes ago ABO Energy ABO Energy drives strategic development and future financing solution forward
Published on 06/23/2026 at 17:53, 1 hour 14 minutes ago LIGHTON: LightOn confirms the total amount of its bond financing
Published on 06/23/2026 at 17:53, 1 hour 14 minutes ago LIGHTON: LightOn confirme le montant total de son financement obligataire
Published on 06/23/2026 at 18:32, 35 minutes ago Communiqué sur la demande de radiation auprès d'Euroclear des Droits à Complément de Prix
Published on 06/23/2026 at 16:47, 2 hours 21 minutes ago Déclaration des transactions sur actions propres réalisées du 15/06/2026 au 19/06/2026
Published on 06/23/2026 at 16:47, 2 hours 21 minutes ago Statement of transactions in own shares from June 15, 2026 to June 19, 2026
Published on 06/23/2026 at 15:44, 3 hours 24 minutes ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 15 au 19 juin 2026
Published on 06/23/2026 at 15:44, 3 hours 24 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from June 15 to June 19 2026
